indazoles has been researched along with Wet Macular Degeneration in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Joussen, AM; Zeitz, O | 1 |
| Eibl, K; Haritoglou, C; Kampik, A; Kernt, M; König, S; Langer, J; Liegl, RG; Siedlecki, J; Thiele, S | 1 |
| Kim, RY; McLaughlin, MM; Paglione, MG; Slakter, J; Suttle, AB; Tolentino, M; Xu, CF; Ye, L | 1 |
| Henderson, L; Hossain, M; Kelly, DS; Singh, R; Trivedi, T; Wurzelmann, JI; Ye, L | 1 |
| Csaky, KG; Danis, RP; Dugel, PU; Fries, MA; Hossain, M; Kelly, DS; Pierce, AJ; Trivedi, T; Wurzelmann, JI; Xu, CF | 1 |
1 review(s) available for indazoles and Wet Macular Degeneration
| Article | Year |
|---|---|
[Eye Drops Instead of Intravitreal Injections? The Dream of Treating Macular Diseases by Topically Administered Drugs].
Topics: Algorithms; Cholestanols; Double-Blind Method; Indazoles; Indoles; Intravitreal Injections; Ophthalmic Solutions; Phenylurea Compounds; Pyrazoles; Pyridines; Pyrimidines; Randomized Controlled Trials as Topic; Sulfonamides; Vascular Endothelial Growth Factor A; Wet Macular Degeneration | 2017 |
3 trial(s) available for indazoles and Wet Macular Degeneration
| Article | Year |
|---|---|
Initial exploration of oral pazopanib in healthy participants and patients with age-related macular degeneration.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Complement Factor H; Female; Genotype; Humans; Indazoles; Male; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Single-Blind Method; Sulfonamides; Treatment Outcome; Visual Acuity; Wet Macular Degeneration; Young Adult | 2013 |
Clinical evaluation of pazopanib eye drops in healthy subjects and in subjects with neovascular age-related macular degeneration.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biological Availability; Double-Blind Method; Female; Healthy Volunteers; Humans; Indazoles; Male; Middle Aged; Ophthalmic Solutions; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Retina; Sulfonamides; Tissue Distribution; Visual Acuity; Wet Macular Degeneration; Young Adult | 2014 |
Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Biomarkers; Double-Blind Method; Female; Fluorescein Angiography; Humans; Indazoles; Intravitreal Injections; Male; Neoplasm Proteins; Ophthalmic Solutions; Pharmacogenetics; Pyrimidines; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Tomography, Optical Coherence; Visual Acuity; Wet Macular Degeneration | 2015 |
1 other study(ies) available for indazoles and Wet Macular Degeneration
| Article | Year |
|---|---|
[Multikinase inhibitors as a new approach in neovascular age-related macular degeneration (AMD) treatment: in vitro safety evaluations of axitinib, pazopanib and sorafenib for intraocular use].
Topics: Angiogenesis Inhibitors; Astrocytes; Axitinib; Cell Survival; Cornea; Dose-Response Relationship, Drug; Endothelial Cells; Endothelium, Corneal; Humans; Imidazoles; Indazoles; Lens, Crystalline; Microscopy, Phase-Contrast; Niacinamide; Optic Disk; Organ Culture Techniques; Oxidative Stress; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Retinal Pigment Epithelium; Sorafenib; Sulfonamides; Trabecular Meshwork; Wet Macular Degeneration | 2013 |